Type your tag names separated by a space and hit enter

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Evidence Summaries

Level of Evidence = B

Amifostine appears not to have significant radioprotective effects on salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer patients.

A Cochrane review 1 included 2 studies with a total of 130 subjects. Amifostine versus placebo showed no statistically significant differences in the incidence of xerostomia (130 patients, two studies), the decrease of scintigraphically measured uptake of technetium-99m by salivary or submandibular glands at twelve months (80 patients, one study), and the reduction of blood pressure (130 patients, two studies). Two patients in one study collapsed after initiation of amifostine therapy and had to be treated by withdrawing the infusion and volume substitution. Both patients recovered without sequelae. None of the included trials investigated death from any cause, morbidity, health-related quality of life or costs.

Comment: The quality of evidence is downgraded by imprecise results (few patients and wide confidence intervals).

References

1. Ma C, Xie J, Chen Q, Wang G, Zuo S. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Cochrane Database Syst Rev 2009 Oct 7;(4):CD007956.  [PMID:19821441]


Copyright © 2017 Duodecim Medical Publications Limited.
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

"Amifostine for Salivary Glands in High-dose Radioactive Iodine Treated Differentiated Thyroid Cancer." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455547/all/Amifostine_for_salivary_glands_in_high_dose_radioactive_iodine_treated_differentiated_thyroid_cancer.
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455547/all/Amifostine_for_salivary_glands_in_high_dose_radioactive_iodine_treated_differentiated_thyroid_cancer. Accessed April 24, 2019.
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/455547/all/Amifostine_for_salivary_glands_in_high_dose_radioactive_iodine_treated_differentiated_thyroid_cancer
Amifostine for Salivary Glands in High-dose Radioactive Iodine Treated Differentiated Thyroid Cancer [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 April 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455547/all/Amifostine_for_salivary_glands_in_high_dose_radioactive_iodine_treated_differentiated_thyroid_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer ID - 455547 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455547/all/Amifostine_for_salivary_glands_in_high_dose_radioactive_iodine_treated_differentiated_thyroid_cancer PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -